Toripalimab Production Cost Reports

The report provides a detailed analysis essential for establishing a toripalimab production plant. It encompasses all critical aspects necessary for toripalimab production, including the cost of toripalimab production, toripalimab plant cost, toripalimab production costs, and the overall toripalimab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a toripalimab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Toripalimab is a humanised monoclonal antibody that selectively blocks the PD-1 receptor on T cells. It prevents cancer cells from evading immune detection and enables the body's immune system to attack tumours more effectively. It is FDA-approved for nasopharyngeal carcinoma (NPC), a rare head-and-neck cancer. It is used in combination with cisplatin and gemcitabine as first-line therapy for adults with metastatic or recurrent locally advanced NPC. It extends progression-free survival compared to chemo alone, and as monotherapy for recurrent, unresectable or metastatic NPC that has progressed after platinum-based chemotherapy. It also treats unresectable or metastatic melanoma after prior systemic therapy failure, with emerging data in other indications like urothelial carcinoma.

The market for toripalimab is influenced by rising nasopharyngeal carcinoma cases. The regulatory approvals for advanced NPC in first-line combination with chemotherapy and second-line monotherapy contribute to its market. The expanding use of PD-1 inhibitors in oncology, and national reimbursement list inclusions in China that enhance patient access boosts its demand. The pricing negotiations in reimbursement programs where the drug demonstrates favourable cost-effectiveness for NPC and NSCLC affect industrial toripalimab procurement. The strict prior authorisation criteria demanding a confirmed NPC diagnosis, prior platinum failure, oncologist prescription, and evidence of tumour response influence its market. Other factors, like drug acquisition costs and supportive care expenses, influence its sourcing.

Raw Material for Toripalimab Production

According to the toripalimab production plant project report, the key raw materials used in the production of toripalimab include Chinese hamster ovary (CHO) cell line and cell culture media.

Production Process of Toripalimab

The extensive toripalimab production cost report consists of the following major industrial production process:

1. From the Chinese hamster ovary (CHO) cell line: The production process of toripalimab uses recombinant DNA technology in Chinese hamster ovary (CHO) cells. The process starts with cell line development from a master cell bank, followed by upstream production involving seed train expansion and large-scale bioreactor culture for antibody expression. The harvesting occurs via centrifugation and depth filtration of the cell culture fluid. After that, multiple purification steps give toripalimab, which is filled into single-use vials.

Toripalimab has the molecular formula of C6548H10104N1728O2054S44 and a molecular weight of 147,310–149,670 Da. It contains two heavy chains, two light chains, and N-linked glycosylation. It has a clear to slightly opalescent, colourless to slightly yellow sterile solution (40 mg/mL) in vials. It has a pH value of 5.5–6.5 with an osmolality in the range of 260 to 340 mOsm/kg. It has an extinction coefficient of 1.416 (mL/mg) cm^-1 and an isoelectric point (pI) around neutral values typical for mAbs. It is stable under recommended refrigerated storage. It binds very strongly to PD-1 and blocks its interactions with PD-L1 and PD-L2, mainly using a specific loop on its heavy chain.